6 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 8 Phase 1, 7 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 2, Recruiting 1 |
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 2 |
| Not applicable | 1 | Completed 1 |
Follow Preleukemia: new trials by email Literature Review of Preleukemia trials Research Report on Preleukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Orca-T - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Recruiting | Orca Biosystems, Inc. | 80 | 2025-12-09 | 2026-07-07 |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome BH-30236, Venetoclax - Leukemia, Leukemia, Myeloid | Phase 1 | Recruiting | BlossomHill Therapeutics | 170 | 2024-06-19 | 2025-09-24 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS Metformin - Preleukemia, Myelodysplastic Neoplasm | Phase 2 | Recruiting | Kirsten Grønbæk | 40 | 2021-12-13 | 2024-11-22 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Decitabine, PDR001, MBG453 - Leukemia, Leukemia, Myeloid | Phase 1 | Completed | Novartis Pharmaceuticals | 241 | 2017-07-06 | 2025-05-18 |
| Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls Samples, Quality of life questionnaire - Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia | Not applicable | Completed | University Hospital, Tours | 138 | 2016-10-25 | 2021-04-19 |
| Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome Sertraline, Bone Marrow Aspirate/Biopsy - Myelodysplastic Syndromes | Phase 1 | Terminated | Gustavo Rivero | 14 | 2015-05-01 | 2022-06-02 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
| A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia ARRY-520, KSP(Eg5) inhibitor; intravenous - Advanced MDS, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Pfizer | 36 | 2008-03-18 | 2021-02-08 |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) lintuzumab, lenalidomide - Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Seagen Inc. | 13 | 2008-03-01 | 2011-10-12 |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies Clofarabine, Melphalan, Campath - Advanced Hematologic Malignancies, Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 82 | 2006-03-01 | 2014-02-27 |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies Fludarabine, Melphalan, Campath - Preleukemia, Myeloproliferative Disorders | Phase 1 | Terminated | University of Chicago | 1 | 2003-05-01 | 2014-03-17 |
| Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant CD34+ enriched, T Cell Depleted donor stem cell product - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | No longer available | Christopher Dvorak | 2021-05-27 |
Myelodysplastic Syndromes (10) · Leukemia (9) · Hematologic Diseases (8) · Leukemia, Myeloid, Acute (8) · Bone Marrow Diseases (7) · Leukemia, Myeloid (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Precancerous Conditions (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoma (4) · Myeloproliferative Disorders (4) · Cytopenia (3)
Hemic and Lymphatic Diseases (14) · Neoplasms (9) · Precancerous Conditions (9) · Hematologic Diseases (6) · Neoplasms by Histologic Type (6) · Bone Marrow Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Leukemia, Myeloid (3) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Anemia (1)
Melphalan (4) · fludarabine (3) · Alemtuzumab (2) · Bone Marrow Transplantation (2) · Busulfan (2) · Cyclophosphamide (2) · Mesna (2) · Mycophenolic Acid (2) · Patient Reported Outcome Measures (2) · Peripheral Blood Stem Cell Transplantation (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · Azacitidine (1) · Biopsy (1)
Center for International Blood and Marrow Transplant Research (2) · University of Chicago (2) · BlossomHill Therapeutics (1) · Christopher Dvorak (1) · Constellation Pharmaceuticals (1) · Gustavo Rivero (1) · Kirsten Grønbæk (1) · Novartis Pharmaceuticals (1) · Orca Biosystems, Inc. (1) · Pfizer (1) · Seagen Inc. (1) · University Hospital, Tours (1)
United States (12) · France (3) · Germany (2) · Netherlands (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · Finland (1) · Italy (1) · Poland (1) · Spain (1)
Steven Devine, MD (2) · Andrew Artz, M.D. (1) · Andrew Artz, MD (1) · Christopher Dvorak, MD (1) · Eric Sievers, MD (1) · Ginna Laport, MD (1) · Gustavo A Rivero, MD (1)
PMID 22139909, PMID 36881782, PMID 37530627, PMID 38259250, PMID 40523209, PMID 42013378, PMID 42448319, PMID 42616616
2016 (1), 2018 (1)